| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.26B | 9.38 | 67 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 692.99M | 4.09 | 10.76 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 932.87M | 2.35 | -1.84 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 630.68M | 8.04 | -2.62 | -117.82% | 0.18 | |||
| IMNMImmunome, Inc. | 2.22B | 20.14 | -4.03 | -35.5% | -23.01% | -84.4% | 0.03 | |
| NKTRNektar Therapeutics | 744.1M | 36.58 | -4.21 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IBRXImmunityBio, Inc. | 2.78B | 2.82 | -4.55 | 22.71% | -422.28% | |||
| CRVSCorvus Pharmaceuticals, Inc. | 485.43M | 6.50 | -6.37 | -21.01% | 0.03 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 7.71M | 15.04M | 71.62M | 59.5M | 57.49M | 68.43M | 37.31M | 53.16M | 101.21M | 138.1M |
| Revenue Growth % | 0.52% | 0.95% | 3.76% | -0.17% | -0.03% | 0.19% | -0.45% | 0.42% | 0.9% | 0.36% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 7.71M | 15.04M | 71.62M | 59.5M | 57.49M | 68.43M | 37.31M | 53.16M | 101.21M | 138.1M |
| Gross Margin % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | 0.52% | 0.95% | 3.76% | -0.17% | -0.03% | 0.19% | -0.45% | 0.42% | 0.9% | 0.36% |
| Operating Expenses | 40.91M | 74.63M | 117.88M | 137.38M | 168.38M | 148.97M | 153.35M | 154.5M | 107.7M | 113.11M |
| OpEx % of Revenue | 5.31% | 4.96% | 1.65% | 2.31% | 2.93% | 2.18% | 4.11% | 2.91% | 1.06% | 0.82% |
| Selling, General & Admin | 12.56M | 19.87M | 25.61M | 33.51M | 36.77M | 36.03M | 39.16M | 42.85M | 30.02M | 29.73M |
| SG&A % of Revenue | 1.63% | 1.32% | 0.36% | 0.56% | 0.64% | 0.53% | 1.05% | 0.81% | 0.3% | 0.22% |
| Research & Development | 28.36M | 54.76M | 92.28M | 103.87M | 131.62M | 112.94M | 114.19M | 111.65M | 77.68M | 83.38M |
| R&D % of Revenue | 3.68% | 3.64% | 1.29% | 1.75% | 2.29% | 1.65% | 3.06% | 2.1% | 0.77% | 0.6% |
| Other Operating Expenses | 0 | -69K | -27K | -68K | -135K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -33.2M | -59.59M | -46.26M | -77.87M | -110.89M | -80.54M | -116.04M | -101.33M | -6.48M | 25M |
| Operating Margin % | -4.31% | -3.96% | -0.65% | -1.31% | -1.93% | -1.18% | -3.11% | -1.91% | -0.06% | 0.18% |
| Operating Income Growth % | -0.12% | -0.79% | 0.22% | -0.68% | -0.42% | 0.27% | -0.44% | 0.13% | 0.94% | 4.85% |
| EBITDA | -32M | -57.85M | -44.61M | -75.99M | -108.29M | -77.97M | -113.34M | -98.89M | -4.31M | 26.76M |
| EBITDA Margin % | -4.15% | -3.85% | -0.62% | -1.28% | -1.88% | -1.14% | -3.04% | -1.86% | -0.04% | 0.19% |
| EBITDA Growth % | -0.1% | -0.81% | 0.23% | -0.7% | -0.43% | 0.28% | -0.45% | 0.13% | 0.96% | 7.21% |
| D&A (Non-Cash Add-back) | 1.21M | 1.73M | 1.65M | 1.88M | 2.6M | 2.57M | 2.71M | 2.44M | 2.17M | 1.77M |
| EBIT | -33.63M | -57.23M | -43.61M | -77.87M | -102.67M | -80.54M | -116.04M | -101.33M | -6.48M | 25M |
| Net Interest Income | -417K | 736K | 2.67M | 7.64M | 8.37M | 1.84M | 255K | 1.68M | 9.84M | 7.14M |
| Interest Income | 1.31M | 2.42M | 2.67M | 7.64M | 8.37M | 1.84M | 255K | 1.68M | 9.84M | 7.14M |
| Interest Expense | 1.73M | 1.69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -2.16M | 667K | 2.65M | 7.57M | 8.23M | 29.63M | 172K | 2.02M | 9.81M | 7.1M |
| Pretax Income | -35.36M | -58.92M | -43.61M | -70.3M | -102.67M | -50.91M | -115.87M | -99.32M | 3.32M | 32.09M |
| Pretax Margin % | -4.59% | -3.92% | -0.61% | -1.18% | -1.79% | -0.74% | -3.11% | -1.87% | 0.03% | 0.23% |
| Income Tax | 10K | -19K | -513K | 14.3M | -427K | 13.91M | 0 | 0 | 3.89M | 224K |
| Effective Tax Rate % | 1% | 1% | 0.99% | 1.2% | 1% | 1.27% | 1% | 1% | -0.17% | 0.99% |
| Net Income | -35.37M | -58.9M | -43.1M | -84.6M | -102.24M | -64.82M | -115.87M | -99.32M | -569K | 31.87M |
| Net Margin % | -4.59% | -3.92% | -0.6% | -1.42% | -1.78% | -0.95% | -3.11% | -1.87% | -0.01% | 0.23% |
| Net Income Growth % | -0.17% | -0.67% | 0.27% | -0.96% | -0.21% | 0.37% | -0.79% | 0.14% | 0.99% | 57.01% |
| Net Income (Continuing) | -35.37M | -58.9M | -43.1M | -84.6M | -102.24M | -64.82M | -115.87M | -99.32M | -569K | 31.87M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.00 | -1.63 | -1.16 | -2.03 | -2.26 | -0.71 | -1.26 | -1.48 | -0.01 | 0.38 |
| EPS Growth % | -0.15% | -0.63% | 0.29% | -0.75% | -0.11% | 0.69% | -0.77% | -0.17% | 0.99% | - |
| EPS (Basic) | -1.00 | -1.63 | -1.16 | -2.03 | -2.26 | -0.71 | -1.26 | -1.48 | -0.01 | 0.38 |
| Diluted Shares Outstanding | 35.49M | 36.23M | 37.17M | 41.66M | 45.34M | 46.15M | 64.15M | 65.74M | 73.81M | 84.75M |
| Basic Shares Outstanding | 35.48M | 36.23M | 37.17M | 41.66M | 45.34M | 46.15M | 64.15M | 65.74M | 73.81M | 84.44M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 189.75M | 188.15M | 388.6M | 445.48M | 303.33M | 324.01M | 310.3M | 237.1M | 182.94M | 107.31M |
| Cash & Short-Term Investments | 186.71M | 181.94M | 374.11M | 436.13M | 296.14M | 316.12M | 305.23M | 193.65M | 174.51M | 100.62M |
| Cash Only | 59.82M | 104.64M | 177.55M | 247.58M | 188.43M | 191.86M | 205.53M | 193.65M | 17.17M | 38.05M |
| Short-Term Investments | 126.89M | 77.29M | 196.56M | 188.55M | 107.72M | 124.26M | 99.7M | 0 | 157.34M | 62.57M |
| Accounts Receivable | 744K | 2.31M | 10.14M | 97K | 13K | 798K | 790K | 35.99M | 3.43M | 3.1M |
| Days Sales Outstanding | 35.21 | 56.12 | 51.67 | 0.59 | 0.08 | 4.26 | 7.73 | 247.07 | 12.38 | 8.2 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 2.3M | 0 | 4.35M | 9.25M | 0 | 0 | 0 | 7.47M | 5M | 3.58M |
| Total Non-Current Assets | 7.46M | 10.98M | 9.04M | 11.63M | 37.95M | 34.65M | 29.11M | 23.79M | 18.86M | 13.23M |
| Property, Plant & Equipment | 3.48M | 4.39M | 4.22M | 6.93M | 32.75M | 29.45M | 25.32M | 21.02M | 16.18M | 10.6M |
| Fixed Asset Turnover | 2.22x | 3.43x | 16.98x | 8.58x | 1.76x | 2.32x | 1.47x | 2.53x | 6.26x | 13.02x |
| Goodwill | 949K | 949K | 949K | 949K | 949K | 949K | 949K | 949K | 949K | 949K |
| Intangible Assets | 1.75M | 1.75M | 1.6M | 1.46M | 1.31M | 1.17M | 1.02M | 875K | 729K | 583K |
| Long-Term Investments | 995K | 0 | 917K | 917K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -115K | 3.89M | 957K | 238K | 2.93M | 3.09M | 1.82M | 944K | 1M | 1.09M |
| Total Assets | 197.22M | 199.13M | 397.64M | 457.11M | 341.28M | 358.66M | 339.41M | 260.89M | 201.79M | 120.53M |
| Asset Turnover | 0.04x | 0.08x | 0.18x | 0.13x | 0.17x | 0.19x | 0.11x | 0.20x | 0.50x | 1.15x |
| Asset Growth % | 1.7% | 0.01% | 1% | 0.15% | -0.25% | 0.05% | -0.05% | -0.23% | -0.23% | -0.4% |
| Total Current Liabilities | 15.74M | 35.77M | 61.15M | 97.91M | 85.59M | 68.11M | 77.87M | 152.61M | 155.91M | 85.77M |
| Accounts Payable | 4.7M | 6.6M | 4.21M | 5.13M | 4.16M | 3M | 2.82M | 2.81M | 1.46M | 1.09M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 2.07M | 4.85M | 11.86M | 20.14M | 0 | 0 | 0 | 0 | 9.44M | 0 |
| Current Ratio | 12.06x | 5.26x | 6.36x | 4.55x | 3.54x | 4.76x | 3.98x | 1.55x | 1.17x | 1.25x |
| Quick Ratio | 12.06x | 5.26x | 6.36x | 4.55x | 3.54x | 4.76x | 3.98x | 1.55x | 1.17x | 1.25x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 55.41M | 84.88M | 266.6M | 228.32M | 204.58M | 298.33M | 262M | 194.03M | 93.33M | 35.22M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 24.87M | 21.68M | 18.06M | 13.97M | 9.38M | 4.24M |
| Deferred Tax Liabilities | 507K | 513K | 398K | 1.14M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 198K | 566K | 1.9M | 3.05M | 850K | 0 | 0 | 0 | 3.89M | 4.12M |
| Total Liabilities | 71.15M | 120.65M | 327.75M | 326.23M | 290.17M | 366.44M | 339.87M | 346.64M | 249.24M | 120.99M |
| Total Debt | 0 | 0 | 0 | 0 | 27.68M | 24.87M | 21.67M | 18.06M | 13.97M | 9.38M |
| Net Debt | -59.82M | -104.64M | -177.55M | -247.58M | -160.74M | -166.99M | -183.86M | -175.59M | -3.2M | -28.67M |
| Debt / Equity | - | - | - | - | 0.54x | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.35x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.07x |
| Interest Coverage | -19.17x | -35.28x | - | - | - | - | - | - | - | - |
| Total Equity | 126.07M | 78.48M | 69.9M | 130.88M | 51.11M | -7.77M | -459K | -85.75M | -47.45M | -456K |
| Equity Growth % | 2.61% | -0.38% | -0.11% | 0.87% | -0.61% | -1.15% | 0.94% | -185.82% | 0.45% | 0.99% |
| Book Value per Share | 3.55 | 2.17 | 1.88 | 3.14 | 1.13 | -0.17 | -0.01 | -1.30 | -0.64 | -0.01 |
| Total Shareholders' Equity | 126.07M | 78.48M | 69.9M | 130.88M | 51.11M | -7.77M | -459K | -85.75M | -47.45M | -456K |
| Common Stock | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | -117.47M | -176.37M | -219.47M | -314.98M | -417.23M | -507.69M | -623.56M | -722.88M | -723.45M | -691.58M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -76K | -27K | -94K | -93K | 57K | -47K | -242K | 10K | 95K | 27K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -27.41M | -2.03M | 170.37M | -75.52M | -140.48M | 5.26M | -119.03M | -110.79M | -56.03M | -86.23M |
| Operating CF Margin % | -3.55% | -0.14% | 2.38% | -1.27% | -2.44% | 0.08% | -3.19% | -2.08% | -0.55% | -0.62% |
| Operating CF Growth % | -1.86% | 0.93% | 84.84% | -1.44% | -0.86% | 1.04% | -23.63% | 0.07% | 0.49% | -0.54% |
| Net Income | -35.37M | -58.9M | -43.1M | -84.6M | -132.82M | -32.88M | -83.61M | -99.32M | -569K | 31.87M |
| Depreciation & Amortization | 1.21M | 1.73M | 1.65M | 1.88M | 2.6M | 2.57M | 2.71M | 5.86M | 2.17M | 1.77M |
| Stock-Based Compensation | 3.99M | 10.1M | 11.29M | 16.88M | 19.1M | 14.79M | 13.17M | 0 | 0 | 7.67M |
| Deferred Taxes | 8K | 6K | -513K | 0 | 0 | -236K | 272K | 0 | 0 | 0 |
| Other Non-Cash Items | 3.01M | 1.77M | 11.09M | -1.7M | 2.05M | 2.89M | 3.13M | 13.33M | 4.87M | -1.12M |
| Working Capital Changes | -248K | 43.26M | 189.97M | -7.98M | -31.41M | 18.13M | -54.7M | -30.65M | -62.51M | -126.42M |
| Change in Receivables | 1.13M | -1.57M | -7.83M | 10.04M | 84K | -785K | 8K | -35.2M | 32.55M | 329K |
| Change in Inventory | 1.81M | -253K | 10.32M | 19.91M | 0 | -11.12M | 11.64M | 0 | 0 | 0 |
| Change in Payables | 2.94M | 1.76M | -2.44M | 261K | -374K | -857K | -139K | 68K | -1.43M | -297K |
| Cash from Investing | -130.56M | 45.86M | -121.27M | 5.93M | 79.7M | -18.72M | 22.49M | 98.26M | -150.67M | 99.7M |
| Capital Expenditures | -1.59M | -2.18M | -1.56M | -3.79M | -3.5M | -2.31M | -1.61M | -1.74M | -840K | -310K |
| CapEx % of Revenue | 0.21% | 0.14% | 0.02% | 0.06% | 0.06% | 0.03% | 0.04% | 0.03% | 0.01% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -817K | 52K | -121.27M | 5.93M | 0 | -16.41M | 24.1M | 0 | 0 | 0 |
| Cash from Financing | 153.4M | 996K | 23.8M | 139.62M | 1.63M | 16.89M | 110.21M | 648K | 30.23M | 7.52M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | -6.71M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 6.97M | 918K | 3.84M | 5.03M | 1.63M | 5.61M | 2.5M | 0 | 0 | 613K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -29.01M | -4.21M | 168.81M | -79.31M | -143.98M | 2.95M | -120.64M | -112.53M | -56.88M | -86.54M |
| FCF Margin % | -3.76% | -0.28% | 2.36% | -1.33% | -2.5% | 0.04% | -3.23% | -2.12% | -0.56% | -0.63% |
| FCF Growth % | -1.96% | 0.85% | 41.12% | -1.47% | -0.82% | 1.02% | -41.89% | 0.07% | 0.49% | -0.52% |
| FCF per Share | -0.82 | -0.12 | 4.54 | -1.90 | -3.18 | 0.06 | -1.88 | -1.71 | -0.77 | -1.02 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.03x | -3.95x | 0.89x | 1.37x | -0.08x | 1.03x | 1.12x | 98.48x | -2.71x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 13.06M | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -148.86% | -57.59% | -58.09% | -84.28% | -112.35% | -299.13% | - | - | - | - |
| Return on Invested Capital (ROIC) | -37.59% | -223% | - | - | - | - | - | - | - | - |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | -458.69% | -391.54% | -60.17% | -142.19% | -177.84% | -94.73% | -310.54% | -186.82% | -0.56% | 23.08% |
| Debt / Equity | - | - | - | - | 0.54x | - | - | - | - | - |
| Interest Coverage | -19.17x | -35.28x | - | - | - | - | - | - | - | - |
| FCF Conversion | 0.78x | 0.03x | -3.95x | 0.89x | 1.37x | -0.08x | 1.03x | 1.12x | 98.48x | -2.71x |
| Revenue Growth | 51.9% | 95.06% | 376.12% | -16.92% | -3.38% | 19.03% | -45.47% | 42.48% | 90.38% | 36.45% |
CytomX Therapeutics, Inc. (CTMX) has a price-to-earnings (P/E) ratio of 10.8x. This may indicate the stock is undervalued or faces growth challenges.
CytomX Therapeutics, Inc. (CTMX) reported $113.6M in revenue for fiscal year 2024. This represents a 12696% increase from $0.9M in 2013.
CytomX Therapeutics, Inc. (CTMX) grew revenue by 36.4% over the past year. This is strong growth.
Yes, CytomX Therapeutics, Inc. (CTMX) is profitable, generating $28.0M in net income for fiscal year 2024 (23.1% net margin).
CytomX Therapeutics, Inc. (CTMX) had negative free cash flow of $72.4M in fiscal year 2024, likely due to heavy capital investments.